Enterprise vision

Restone Biomedical Co., Ltd. ( hereinafter referred to as " Restone" ) officially announced that the US FDA approved the Phase II clinical research application of SHR 0302, a new small molecule JAK 1 inhibitor declared by the company. Dr. Wang Min, CEO of the company, said: " Ruishi is committed to bringing innovative drugs developed in China to the world, and the approval of this clinical trial in the United States is an important starting point and a milestone for Restone